Chronic Hepatitis C with HIV co-infection study

This research study will include patients who are infected with chronic hepatitis C (HCV) and human immunodeficiency virus (HIV). Patients who are treatment naïve (those who have never been previously treated with prescription anti-HCV medications) will be randomly assigned to receive either 8 or 12 weeks of daclatsvir plus sofosbuvir. Those patients who are treatment experienced (received prior prescription anti-HCV medications) will receive 12 weeks of combination therapy. After the 12 weeks of taking the study drugs, there will be 24 weeks of follow-up (post-treatment visits). There is a pharmacogenetic sub-study.